Table 2.
Patient demographics
| Characteristic | Surgery alone (N=15) | Neoadjuvant therapy (N=9) | Adjuvant therapy (N=40) | Neoadjuvant & adjuvant therapy (N=9) | Total (N=73) | P value |
|---|---|---|---|---|---|---|
| Age at diagnosis-years, mean (SD) | 70.6 (8.6) | 61.7 (12.9) | 65.4 (10.3) | 63.1(7.1) | 0.1341 | |
| >65 years old | 11 (73.3%) | 5 (55.6%) | 18 (45.0%) | 4 (44.4%) | 38 (52.1%) | 0.2802 |
| Gender | 0.3902 | |||||
| Female | 9 (60.0%) | 5 (55.6%) | 15 (37.5%) | 3 (33.3%) | 32 (43.8%) | |
| Male | 6 (40.0%) | 4 (44.4%) | 25 (62.5%) | 6 (66.7%) | 41 (56.2%) | |
| Race | 0.1512 | |||||
| White | 12 (80.0%) | 7 (77.8%) | 37 (92.5%) | 7 (77.8%) | 63 (86.3%) | |
| African-American | 0 (0.0%) | 0 (0.0%) | 1 (2.5%) | 1 (11.1%) | 2 (2.7%) | |
| American Indian | 1 (6.7%) | 1 (11.1%) | 2 (5.0%) | 0 (0.0%) | 4 (5.5%) | |
| Asian | 1 (6.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (1.4%) | |
| Unknown | 1 (6.7%) | 1 (11.1%) | 0 (0.0%) | 1 (11.1%) | 3 (4.1%) | |
| Ethnicity | 0.5882 | |||||
| Non-Hispanic | 12 (80.0%) | 6 (66.7%) | 34 (85.0%) | 7 (77.8%) | 59 (80.8%) | |
| Hispanic | 3 (20.0%) | 2 (22.2%) | 5 (12.5%) | 2 (22.2%) | 12 (16.4%) | |
| Unknown | 0 (0.0%) | 1 (11.1%) | 1 (2.5%) | 0 (0.0%) | 2 (2.7%) | |
| Performance status ECOG score | 0.0332 | |||||
| 0 | 0 (0.0%) | 2 (22.2%) | 11 (27.5%) | 4 (44.4%) | 17 (23.3%) | |
| 1 | 10 (66.7%) | 7 (77.8%) | 24 (60.0%) | 3 (33.3%) | 44 (60.3%) | |
| 2 | 5 (33.3%) | 0 (0.0%) | 5 (12.5%) | 2 (22.2%) | 12 (16.4%) | |
| Preoperative CA 19-9 mean U/mL (SD) | 217.9 (287.9) | 1,285.6 (1,732.4) | 282.0 (487.8) | 1,444.7 (2,117.7) | 547.5 (1,116.7) | 0.0053 |
| Biliary stent placement | 10 (66.7%) | 5 (55.6%) | 26 (65%) | 6 (66.7%) | 47 (64.3) | 0.8542 |
1
, ANOVA;
2
, Fisher’s Exact Test;
3
, Kruskal-Wallis Rank Sum Test.
ECOG, Eastern Cooperative Oncology Group; CA 19-9, carbohydrate antigen 19-9.